Primary Peritoneal Serous Papillary Carcinoma: A Study of 25 Cases and Comparison with Stage III–IV Ovarian Papillary Serous Carcinoma

Ben‐Baruch, Gilad; Sivan, Eyal; Moran, Orit; Rizel, Shulamit; Menczer, Joseph; Seidman, Daniel S.

doi:10.1006/gyno.1996.0060

Cited by 87 publications

(42 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients with primary peritoneal carcinoma tend to be older, 32,33 and when suboptimally debulked may have better survival rates than ovarian serous carcinoma patients. 3,34,35 The prognosis of primary peritoneal carcinoma compared to ovarian serous carcinoma of the same stage is controversial with some studies reporting worse, same or better survival. 32,36,37 A more recent matched case-comparison study demonstrated platinum resistance and impaired survival in patients with advanced primary peritoneal carcinomas.…”

Section: Discussionmentioning

confidence: 99%

Potentially important microRNA cluster on chromosome 17p13.1 in primary peritoneal carcinoma

et al. 2009

View full text Add to dashboard Cite

MicroRNAs are a group of small non-coding RNAs approximately 22 nucleotides in length. Recent work has shown differential expression of mature microRNAs in human cancers. We characterized the alteration in expression of a select group of microRNAs in primary peritoneal carcinoma relative to matched cases of ovarian serous carcinoma. MicroRNA expression was analysed using semi-quantitative stem-loop RT-PCR on a set of 34 formalin-fixed paraffin-embedded samples. Protein expression of p53 and bcl-2 was quantified in the corresponding tissue microarray. We provide definitive evidence that there is downregulation of a select group of microRNAs in tumours meeting Gynaecological Oncology Group criteria for primary peritoneal carcinoma relative to ovarian serous carcinoma. Specifically, we show decreased p53 expression and downregulation of miR-195 and miR-497 from the microRNA cluster site at chromosome 17p13.1 in primary peritoneal carcinoma relative to ovarian serous carcinoma. miR-195 and miR-497 may have potential roles as tumour-suppressor genes in primary peritoneal tumourigenesis.

show abstract

Section: Discussionmentioning

confidence: 99%

Potentially important microRNA cluster on chromosome 17p13.1 in primary peritoneal carcinoma

et al. 2009

View full text Add to dashboard Cite

show abstract

“…It is generally suggested that PPC should be managed following the treatment regimens established for EOC (Piver et al, 1997;Eltabbakh et al, 1998a). However, controversy exits concerning Journal of Zhejiang University SCIENCE B ISSN 1673-1581 (Print); ISSN 1862-1783 (Online) www.zju.edu.cn/jzus; www.springerlink.com E-mail: jzus@zju.edu.cn the ability to perform optimal surgical debulking and its clinical significance in PPC (Fromm et al, 1990;Ben-Baruch et al, 1996;Eltabbakh et al, 1998a). So far only a few studies have examined the molecular changes associated with PPC and do not find a definite prognostic factor.…”

Section: Introductionmentioning

confidence: 99%

Advanced primary peritoneal carcinoma: clinicopathological and prognostic factor analyses

Chao

Cui

et al. 2008

J. Zhejiang Univ. Sci. B

View full text Add to dashboard Cite

Abstract:Objective: To investigate the factors favoring a positive prognosis for advanced primary peritoneal carcinoma (PPC). Methods: Twenty-four cases meeting the criteria for PPC were analyzed retrospectively for the clinicopathologic profiles. Immunohistochemistry was used to determine the expressions of p53, Top2α, Ki-67 and Her-2/neu. Then all these clinicopathological factors and molecular markers were correlated with the prognosis. Results: There were 15 cases of primary peritoneal serous papillary carcinoma (PPSPC), 6 cases of mixed epithelial carcinoma (MEC) and 3 cases of malignant mixed Mullerian tumor (MMMT). All patients underwent cytoreductive surgery with optimal debulking achieved in 3 cases. Among those receiving first-line chemotherapy, 13 patients received the TP regimen (paclitaxel-cisplatin or carboplatin) and 7 patients received the PAC regimen (cisplatin-doxorubicin-cyclophosphamide). The median overall survival of all patients was 42 months, while the breakdown for survival time for patients with PPSPC, MMT and MEC was 44, 13 and 19 months, respectively. The expressions of p53, Top2α and Ki-67 were all demonstrated in 11 cases respectively. None showed the expression of Her-2/neu. There were significant differences in the median survival between patients with PPSPC and those with MMMT (44 months vs 13 months, P<0.05), also between patients receiving TP combination and those receiving the PAC regimen (75 months vs 28 months, P<0.05).Another significant difference in the median progression-free survival (PFS) was identified between patients with positive p53 immunostaining and those with negative p53 immunostaining (15 months vs 47 months, P<0.05), whereas age, menopausal status, residual tumor size and the other molecular factors did not significantly impact survival. Conclusion: Patients with PPC should be treated with a comprehensive management plan including appropriate cytoreductive surgery and responsive chemotherapy. Overestimating an optimal debulking surgery may not benefit survival. The pathologic subtype, chemotherapy regimen and p53 overexpression were significant prognostic factors.

show abstract

“…In PSPC, the prognosis of the patients treated with chemotherapy alone, especially in those intensive intravenous chemotherapy cannot be done, is generally poor (10,24). In contrast, mean survival periods of those treated with both cytoreductive surgery and intensive platinum-based chemotherapy have been reported to be 17-24 months (25)(26)(27). Here, one patient (case 3) lived for 58 months without recurrence of the tumor by optimal cytoreductive surgery together with intensive intravenous and intraperitoneal chemotherapy, and another (case 4) is still living for 20 months with intensive intravenous and intrathoracic chemotherapy.…”

Section: Discussionmentioning

confidence: 90%

Peritoneal Serous Papillary Adenocarcinoma: Report of Four Cases

et al. 2005

View full text Add to dashboard Cite

We report four cases of peritoneal serous papillary adenocarcinoma (PSPC), a rare disease; all patients had ascites and high levels of serum CA125. Clinical and radiological examinations could not differentiate the disease from peritoneal metastatic tumors and mesothelioma, and histopathological analysis including immunochemistry on the specimen obtained at laparotomy or laparoscopy was necessary for the diagnosis.

show abstract

Primary Peritoneal Serous Papillary Carcinoma: A Study of 25 Cases and Comparison with Stage III–IV Ovarian Papillary Serous Carcinoma

Cited by 87 publications

References 3 publications

Potentially important microRNA cluster on chromosome 17p13.1 in primary peritoneal carcinoma

Potentially important microRNA cluster on chromosome 17p13.1 in primary peritoneal carcinoma

Advanced primary peritoneal carcinoma: clinicopathological and prognostic factor analyses

Peritoneal Serous Papillary Adenocarcinoma: Report of Four Cases

Contact Info

Product

Resources

About